Evidence map›Paper›PMID 28755776›Full record

ArticleJournal of substance abuse treatment2017

The Mental Health Parity and Addiction Equity Act evaluation study: Impact on specialty behavioral healthcare utilization and spending among enrollees with substance use disorders.

Sarah Friedman, Haiyong Xu, Jessica M Harwood, Francisca Azocar, Brian Hurley, Susan L Ettner

Abstract readEvaluation Study
In one paragraph

Article in Journal of substance abuse treatment, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. A Behavioral Economic Model of Help-Seeking for Depression.Perspectives on behavior science · 2021
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sarah FriedmanDepartment of Health Policy and Management, Fielding School of Public Health, University of California, Los Angeles, 911 Broxton Avenue, Los Angeles, CA 90024, United States; Division of General Internal Medicine and Health Services Research, Department of Medicine, David Geffen School of Medicine, UCLA, 911 Broxton Avenue, Los Angeles, CA 90024, United States; School of Community Health Sciences, Division of Health Sciences, University of Nevada, 1664 N. Virginia Street, Reno, NV 89557, United States. Electronic address: Sfriedman@unr.edu.
Haiyong XuDivision of General Internal Medicine and Health Services Research, Department of Medicine, David Geffen School of Medicine, UCLA, 911 Broxton Avenue, Los Angeles, CA 90024, United States. Electronic address: HXu@mednet.ucla.edu.
Jessica M HarwoodDivision of General Internal Medicine and Health Services Research, Department of Medicine, David Geffen School of Medicine, UCLA, 10940 Wilshire Boulevard, Suite 700, Los Angeles, CA 90024, United States. Electronic address: JHarwood@mednet.ucla.edu.
Francisca AzocarOptum®, United Health Group, 425 Market Street, 14th Floor, San Francisco, CA 94105, United States. Electronic address: Francisca.Azocar@optum.com.
Brian HurleyDepartment of Family Medicine, David Geffen School of Medicine, University of California, Los Angeles, 50-078 Center for Health Sciences, Box 951683, Los Angeles, CA 90095, United States. Electronic address: bhurley@ucla.edu.
Susan L EttnerDepartment of Health Policy and Management, Fielding School of Public Health, University of California, Los Angeles, 911 Broxton Avenue, Los Angeles, CA 90024, United States; Division of General Internal Medicine and Health Services Research, Department of Medicine, David Geffen School of Medicine, UCLA, 911 Broxton Avenue, Los Angeles, CA 90024, United States. Electronic address: SEttner@mednet.ucla.edu.

Funding

UCLA Clinical and Translational Science InstituteTL1TR000121 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$2.7M
Parity and Addiction Act: Impact on Benefits, Use and CostsR01DA032619 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ETTNER, SUSAN LOUISE · 2012 to 2015
$2.2M
The effects of three insurance benefit design features on specialty mental health utilization and expendituresR36HS024866 · AHRQ · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI FRIEDMAN, SARAH A · 2016 to 2016
$39k
AHRQ HHS R36 HS024866NCATS NIH HHS TL1 TR000121NIDA NIH HHS R01 DA032619
6 · The paper itself

Abstract

backgroundThe federal Mental Health Parity and Addiction Equity Act (MHPAEA) sought to eliminate historical disparities between behavioral health and medical health insurance benefits among the commercially insured. This study determines whether MHPAEA was associated with increased BH expenditures and utilization among a population with substance use disorder (SUD) diagnoses.

methodsClaims and eligibility data from 5,987,776 enrollees, 2008-2013, were obtained from a national, commercial, managed behavioral health organization. An interrupted time series study design with segmented regression analysis estimated time trends of per-member-per-month (PMPM) spending and use before (2008-2009), during (2010), and after (2011-2013) MHPAEA compliance. The study sample contained individuals with drug or alcohol use disorder diagnosis during study period (N=2,716,473 member-month observations). Outcomes included: total, plan, patient out-of-pocket spending; outpatient utilization (assessment/diagnostic evaluation visits; medication management; individual, group and family psychotherapy, and structured outpatient care); intermediate care utilization (day treatment; recovery home and residential); and inpatient utilization.

resultsStarting at the beginning of the post-parity period, MHPAEA was associated with increased levels of PMPM total and plan spending ($25.80 [p=0.01]; $28.33 [p=0.00], respectively), as well as the number of PMPM assessment/evaluation, individual psychotherapy, and group psychotherapy visits, and inpatient days (0.01 visits [p=0.01]; 0.02 visits [p=0.01]; 0.01 visits [p=0.03]; 0.01days [p=0.01], respectively). Following these initial level changes, MHPAEA was also associated with monthly increases in PMPM total, plan, and patent out-of-pocket spending ($2.56/month [p=0.00]; $2.25/month [p=0.00]; $0.27 [p=0.03], respectively), as well as structured outpatient visits and inpatient days (0.0012 visits/month [p=0.01]; 0.0012days/month [p=0.00]).

conclusionMHPAEA was associated with modest increases in total, plan, and patient out-of-pocket spending and outpatient and inpatient utilization. These increases, while modest in magnitude, are larger in magnitude than increases detected among a sample of all enrollees (i.e. not only those with SUD diagnoses).

Indexed as

AdultFemaleHealth ExpendituresHealth PolicyHealth Status DisparitiesHumansInsurance Claim ReviewInsurance, HealthMaleMental Health ServicesMiddle AgedSubstance-Related DisordersBehavioral health careClaims dataCommercial health insurancePolicy evaluationSubstance use disorder

Identifiers

PMID28755776
PMCPMC6224161

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.